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ABSTRACT 
Vitamin B6 includes six water-soluble vitamers: 
pyridoxal (PL), pyridoxamine (PM), pyridoxine 
(PN), and their phosphorylated forms. Pyridoxal 5'-
phosphate (PLP) is an important cofactor for many 
metabolic enzymes. Several lines of evidence 
demonstrate that blood levels of PLP are 
significantly lower in patients with inflammation 
than in control subjects, and that vitamin B6 has 
anti-inflammatory effects, with therapeutic 
potential for a variety of inflammatory diseases. 
Although one of our group (NK) previously 
demonstrated that PL inhibits the NF-κB pathway, 
the molecular mechanism by which vitamin B6 
suppresses inflammation is not well understood. 
Here, we showed that both PL and PLP suppressed 
the expression of cytokine genes in macrophages by 
inhibiting TLR-mediated TAK1 phosphorylation 
and the subsequent NF-κB and JNK activation. 
Furthermore, PL and PLP abolished NLRP3-
dependent caspase-1 processing and the subsequent 
secretion of mature IL-1β and IL-18 in LPS-primed 
macrophages. In contrast, PM and PN had little 
effect on IL-1β production. PLP, but not PL, 
markedly reduced the production of mitochondrial 
reactive oxygen species (ROS) in peritoneal 
macrophages. Importantly, PL and PLP reduced the 
IL-1β production induced by LPS and ATP, or by 
LPS alone, in mice. Moreover, PL and PLP 
protected mice from lethal endotoxic shock. 
Collectively, these findings reveal novel anti-
inflammatory activities for vitamin B6, and suggest 
its potential for preventing inflammatory diseases 
driven by the NLRP3 inflammasome. 
 
 
Vitamin B6 is ingested from a variety of foods, 
and can also be taken as a dietary supplement or 
clinical drug. The B6 vitamer Pyridoxal 5'-
phosphate (PLP)2 is an essential cofactor for many 
enzymes involved in amino acid metabolism. There 
is growing evidence that vitamin B6 has anti-
inflammatory activity. Epidemiological evidence 
indicates that patients with inflammation have 
significantly lower blood levels of PLP than control 
subjects (1,2). In patients with rheumatoid arthritis, 
high-dose vitamin B6 supplementation 
(100 mg/day) suppresses plasma IL-6 and TNF-α 
levels (3). Both human and animal studies have 
demonstrated an inverse relationship between 
vitamin B6 and colon cancer (4,5). Recent clinical 
trials found that in Alzheimer’s patients, B-vitamin 
supplementation (folic acid, vitamin B6, and 
vitamin B12) slowed the shrinkage of the whole 
brain and decreased atrophy in specific regions of 
the brain (6). A low vitamin B6 intake is associated 
with an increased risk of Parkinson’s disease (7). 
Since inflammatory mechanisms are implicated in 
these diseases, vitamin B6 may be useful in 
preventing inflammatory diseases. Notably, B6 
vitamer pyridoxal (PL) inhibits the LPS-induced 
activation of NF-κB, which is an important 
transcription factor for many inflammation-related 
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genes, in mouse macrophage RAW264.7 cells (8). 
However, the anti-inflammatory mechanisms of 
vitamin B6 are poorly understood. 
The pleiotropic inflammatory cytokine IL-1β, 
which is primarily produced by myeloid cells such 
as monocytes and macrophages, induces the 
proliferation and/or production of other 
inflammatory cytokines, leukocyte adhesion 
molecules, or acute-phase proteins in leukocytes, 
myeloid cells, endothelial cells, hepatocytes, and so 
forth (9). IL-1β is synthesized as a precursor form 
(proIL-1β) that has to be proteolytically processed 
into a mature form to gain biological activity (10). 
The former step (proIL-1β synthesis) is mainly 
regulated by a cytoplasmic signaling pathway that 
activates NF-κB (signal 1), which is triggered, for 
example, by TLRs. The latter step (IL-1β 
processing) can be catalyzed by several proteases; 
of these, caspase 1 is the most important, as shown 
by the severe defects in mature IL-1β production in 
caspase-1-deficient mice (11,12). 
Caspase 1 is also synthesized as an inactive 
precursor, and is fully activated by autoprocessing. 
The cytoplasmic signaling pathway that activates 
caspase 1 (signal 2) has been extensively studied 
recently, revealing that the inflammasome, which is 
a cytoplasmic multiprotein complex consisting of 
sensor proteins (such as NLRP3, NLRC4, or AIM2), 
adaptor proteins (ASC), and caspase 1, forms a 
platform to activate caspase 1 (10,13). Of the sensor 
proteins, NLRP3 has been studied most intensively 
because it responds (directly or indirectly) not only 
to pathogen-associated molecules (such as bacterial 
ionophores, pore-forming toxins, and bacterial and 
viral RNA), but also to a variety of environmental 
and endogenous inflammatory substances 
(including asbestos, silica, ATP, urate crystals, β-
amyloids, cholesterol crystals, and even fatty acids) 
(14-22). Accordingly, NLRP3 has been implicated 
in a variety of inflammatory diseases, including 
inflammatory bowel disease, gout, Alzheimer’s 
disease, arteriosclerosis, and diabetes (19,21,23-28). 
In addition, NLRP3 mutations are known to cause 
autoinflammatory syndromes that are collectively 
called cryopyrin-associated periodic syndrome, or 
CAPS (29). 
In this study, we demonstrate a novel role of 
vitamin B6 in suppressing IL-1β production by 
inhibiting the activation of the NLRP3 
inflammasome. Furthermore, we showed that 
vitamin B6 prevented LPS-induced endotoxic 
shock in vivo, suggesting that the NLRP3 




Vitamin B6 inhibited LPS-induced NF-κB and 
JNK activation and gene expression—We initially 
investigated the overall effect of vitamin B6 on IL-
1β secretion from macrophages stimulated with 
LPS plus ATP. To this end, thioglycollate-induced 
peritoneal macrophages were cultured for 24 h with 
or without B6 vitamer supplementation (500 µM), 
and sequentially stimulated with LPS (TLR4 
agonist) and ATP (NLRP3 activator) to induce IL-
1β secretion. Under these conditions, IL-1β 
secretion was strongly inhibited by PL or PLP but 
not by pyridoxamine (PM) or pyridoxine (PN) (Fig. 
1A). Titration experiments indicated that as little as 
50 µM PL or PLP significantly suppressed IL-1β 
secretion (Fig. 1B). The LPS-induced intracellular 
accumulation of proIL-1β and secretion of IL-6 and 
TNF-α were also inhibited by PL or PLP, but not 
by PM or PN (Fig. 1, C-E). Furthermore, the LPS-
induced expression of Il1b, Il6, Ptgs2, and Ccl2 
mRNAs in peritoneal macrophages was inhibited 
by PL or PLP, but not by PM or PN (Fig. 1, F-I).  
PL and PLP, and although to a lesser extent PM and 
PN suppressed Nlrp3 mRNA expression. (Fig. 1J). 
These results were consistent with the previous 
findings that PL inhibited LPS-induced NF-κB 
activation and expression of NF-κB-target genes 
(Nos2 and Ptgs2) in the Raw264.7 mouse 
macrophage cell line (8). Actually, Western blot 
analyses indicated that events upstream of LPS-
induced NF-κB activation, including the 
phosphorylation of TAK1 and IκB kinases and the 
degradation of IκBα, were severely suppressed by 
PL or PLP (Fig. 1K). PL and PLP also inhibited the 
LPS-induced JNK phosphorylation (Fig. 1K), 
which occurs downstream of TAK1 and contributes 
to IL-1β gene expression (30,31). 
In addition, PL and PLP inhibited the IL-6 and 
TNF-α production induced by other TLR ligands, 
including the TLR3 ligand poly(I:C), the TLR2 
ligand Pam3CSK4, the TLR7 ligand R837, and 
CpG oligodeoxynucleotides, which are TLR9 
ligands (Fig. 2). Taken together, our results 
demonstrate that not only PL, but also PLP 
negatively regulate the TLR-mediated activation of 
Vitamin B6 suppresses NLRP3 inflammasome 
3 
NF-κB and MAPK pathways by inhibiting Tak1 
phosphorylation, and thereby inhibit the expression 
of cytokines genes including Il1b in primary 
macrophages. 
 
Vitamin B6 suppressed NLRP3 inflammasome 
activation—To further investigate the effect of 
vitamin B6 on signal 2, which leads to the 
proteolytic maturation of IL-1β, peritoneal 
macrophages were cultured with LPS for 16 h to 
fully induce intracellular proIL-1β accumulation, 
then treated with B6 vitamers, and stimulated with 
ATP for 6 h to activate the NLRP3 inflammasome. 
Under these conditions, IL-1β secretion was again 
inhibited by as little as 50 µM PL or PLP, but not 
by 500 µM PM or PN (Fig. 3, A and B). The IL-1β 
secretion induced by other NLRP3 activators such 
as nigericin, R837, and monosodium urate (MSU) 
crystals was also inhibited by PL and PLP (Fig. 3C). 
The secretion of IL-18, which, like IL-1β 
undergoes proteolytic maturation catalyzed by 
caspase-1, was also suppressed by PL and PLP (Fig. 
3D). In contrast, neither PL nor PLP added after 
LPS treatment affected the secretion of IL-6, an 
NF-κB-dependent but caspase-1-independent 
cytokine (Fig. 3E). In addition, ATP treatment after 
LPS priming induced no more phosphorylation of 
TAK1 and IκB kinases and degradation of IκBα, 
and PL and PLP did not affect these events (Fig. 
3F). These data indicated that the suppression of 
IL-1β secretion by PL and PLP under these 
conditions was not due to the inhibition of NF-κB. 
Western blot analyses indicated that PL and PLP 
inhibited the generation of mature IL-1β (p17) and 
of the p10 fragment of mature caspase-1, when 
these vitamers were added after LPS treatment and 
before ATP stimulation (Fig. 3G). However, the 
LPS-induced NLRP3 and proIL-1β expression and 
the constitutive caspase-1 expression at both 
mRNA and protein levels were not inhibited by PL 
or PLP (data not shown and Fig. 3G), consistent 
with the notion that NF-κB-dependent gene 
expression was not inhibited under these conditions. 
Inflammasome activation induces pyroptosis, a 
caspase-1-dependent programmed cell death. 
Pyroptotic cells rupture rapidly, releasing lactate 
dehydrogenase (LDH) and other cytoplasmic 
contents. Pyroptosis would also facilitate the IL-1β 
release from macrophages. PL and PLP inhibited 
the LDH release from macrophages at 1 h, 2 h and 
3 h, but not 6 h after ATP stimulation (Fig. 3I). 
These results indicate that PL and PLP delayed 
pyroptosis; however, their suppression of IL-1β 
secretion at 6 h was not due to the inhibition of 
pyroptosis (Fig. 3H).  
Taken together, these results indicate that PL 
and PLP can inhibit the signal 2 mediated by the 
NLRP3 inflammasome. 
 
Vitamin B6 did not affect the signal 2 mediated 
by the NLRC4 and AIM2 inflammasomes—The 
NLRP3, NLRC4, and AIM2 inflammasomes can be 
specifically activated by different bacterial species 
under certain conditions. For example, 
Staphylococcus (S). aureus and Salmonella (S.) 
typhimurium at the logarithmic growth phase 
activate mainly the NLRP3 and NLRC4 
inflammasome, respectively (32-34). In contrast, 
the infection of unprimed macrophages with 
Listeria (L.) monocytogenes followed by penicillin 
G treatment, which causes intracellular releases of 
bacterial DNA, induces the AIM2-dependent 
secretion of IL-1β (35). 
To investigate whether PL and PLP inhibit the 
IL-1β production induced by S. aureus and S. 
typhimurium, unprimed macrophages and LPS-
primed macrophages were treated with PL or PLP 
and then infected with the bacteria. In unprimed 
macrophages, the signal 1 for proIL-1β production 
depended on the bacterial infection. Under such 
conditions, PL and PLP inhibited the IL-1β 
production induced by either of these bacterial 
species (Fig. 4, A and B). However, in LPS-primed 
macrophages (in which proIL-1β had already been 
produced), PL and PLP inhibited the IL-1β 
production induced by S. aureus but not by S. 
typhimurium (Fig. 4, C and D). 
To further investigate the effect of PL and PLP 
on the AIM2 inflammasome, macrophages were 
infected with L. monocytogenes, which provides 
Signal 1 through TLR2-dependent recognition of 
cell wall components (36). The infected cells were 
cultured with PL or PLP for 2h, and then treated 
with penicillin G, leading to bacterial cell lysis and 
DNA release into the cytoplasm followed by 
inflammasome activation that largely depends on 
AIM2 (35). Under these conditions, PL and PLP 
did not affect the secretion of IL-1β (Fig. 4E). 
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Vitamin B6 suppressed noncanonical IL-1β 
secretion and pyroptosis induced by LPS 
transfection—We also investigated the effect of PL, 
and PLP on noncanonical NLRP3 inflammasome-
dependent IL-1β secretion induced by LPS 
transfection in Pam3CSK4-primed peritoneal 
macrophages. Both PL and PLP suppressed IL-1β 
secretion (Fig. 4F) under these conditions. As this 
response requires NLRP3-inflammasome (37), IL-
1β production was not observed in ASC-deficient 
macrophages (Fig. 4F). Under the same conditions, 
pyroptosis is induced by caspase-11-dependent but 
NLRP3-inflammasome-independent manner (37). 
Consistently, ASC-/- macrophages released LDH to 
a similar extent as wild-type macrophages (Fig. 4G). 
Importantly, PL and PLP reduced the LDH release, 
suggesting that PL and PLP could inhibit caspase-
11-dependent pyroptosis (Fig. 4G). 
These results indicate that PL and PLP 
commonly inhibit the signal 1 induced by different 
bacteria, but specifically inhibit the signal 2 
mediated by the NLRP3 inflammasome and not by 
the NLRC4 or the AIM2 inflammasome. 
 
Vitamin B6 inhibited signal 1 and signal 2 for 
the IL-1β production in human cells—To test the 
inhibitory effects of vitamin B6 on the IL-1β 
secretion requiring signal 1 and signal 2 and on the 
TNF-α secretion that requires only signal 1 in 
human cells, we used macrophagic cells 
differentiated from the THP-1 human monocytic 
cell line by PMA treatment (THP-1 macrophages). 
The THP-1 macrophages were treated with PL or 
PLP before or after LPS treatment, and then 
stimulated with nigericin to activate the NLRP3 
inflammasome. As expected, potent IL-1β 
secretion was observed after sequential stimulation 
with LPS and nigericin, while TNF-α secretion was 
fully induced by LPS stimulation alone; nigericin 
did not affect the TNF-α production (Fig. 5, A-D). 
When the THP-1 macrophages were treated with 
PL or PLP before LPS was added, the secretion of 
both IL-1β and TNF-α was inhibited (Fig. 5, A and 
B). In contrast, when PL or PLP were added after 
LPS treatment, only the IL-1β secretion was 
inhibited; TNF-α secretion was unaffected (Fig. 5, 
C and D). These results, which were consistent with 
our results using mouse peritoneal macrophages, 
suggest that PL and PLP inhibit both signal 1 and 
signal 2 in human cells. 
 
Vitamin B6 suppressed ASC speck formation 
and oligomerization—ASC forms large aggregates 
called ‘specks’ when inflammasomes are activated. 
ASC speck formation is suggested to be involved in 
efficient caspase-1 activation and IL-1β processing. 
Therefore, we investigated whether PL and PLP 
inhibited ASC speck formation. ASC specks 
formed when LPS-primed peritoneal macrophages 
were stimulated with nigericin (Fig. 6A, upper 
panels, 6B). However, treating LPS-primed 
macrophages with PL or PLP prior to nigericin 
stimulation strongly inhibited the ASC speck 
formation (Fig. 6A, middle and lower panels, 6B). 
Consistently, PL and PLP inhibited ASC 
oligomerization under the same conditions (Fig. 
6C). Taken with our observation that PL and PLP 
selectively inhibit the NLRP3 inflammasome, these 
results suggest that PL and PLP inhibit signal 2 by 
targeting NLRP3 or upstream events that induce the 
NLRP3 inflammasome. 
 
Mitochondrial ROS production was inhibited by 
PLP but not by PL—Because the NLRP3 
inflammasome is activated by structurally diverse 
molecules, it has been postulated that different 
activators induce common intracellular events that 
eventually cause NLRP3 inflammasomes to form. 
The efflux of K+ and the resulting decrease in 
intracellular K+ concentration has been proposed as 
a common upstream event in NLRP3 
inflammasome formation (10,38). Therefore, we 
measured the cellular potassium levels using 
inductively coupled plasma mass spectrometry. 
Consistent with previous findings (38), treating 
LPS-primed macrophages with ATP or nigericin 
decreased the cellular potassium level. This event 
was not affected by PL or PLP treatment (Fig. 6D). 
Mitochondrial reactive oxygen species (ROS) 
generation has also been proposed as a common 
upstream event in NLRP3 activation (39). 
Consistently, treating LPS-primed macrophages 
with ATP enhanced the MitoSox Red fluorescence, 
indicating elevated mitochondrial ROS generation 
(Fig. 6E). Furthermore, Mito-TEMPO, a 
mitochondria-targeted antioxidant that inhibited 
ATP-induced mitochondrial ROS elevation 
suppressed IL-1β production in LPS-primed 
macrophages (Fig. 6, E and F). Mito-temp also 
inhibited IL-1β production induced by other 
NLRP3 activators (Fig. 6F). Because vitamin B6 
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also acts as an antioxidant (40), we examined 
whether PL and PLP could inhibit mitochondrial 
ROS generation. Interestingly, this event was 
markedly inhibited by PLP but not by PL (Fig. 6G). 
These results indicate that PLP has a potential to 
suppress mitochondrial ROS generation, which can, 
at least in part, explain the PLP’s activity to inhibit 
NLRP3-dependent IL-1β production. 
 
Vitamin B6 inhibited IL-1β production in mice 
and protected mice against LPS-induced endotoxic 
shock-Finally, we examined the in vivo effects of 
PL and PLP. We induced IL-1β production in ICR 
mice by i.p. injections of a low dose of LPS (2 
µg/kg-bw) followed by ATP (50 µmole/kg-bw) 
(41,42), or in C57BL/6 mice by a high dose of LPS 
(20 mg/kg-bw) alone (43). In both experimental 
systems, the serum and/or peritoneal IL-1β levels 
were suppressed by injecting 20 mg/kg-bw PL or 
PLP (Fig. 7, A-D). In contrast, PL or PLP did not 
significantly suppress the serum or peritoneal TNF-
α levels (Fig. 7, E and F). 
Injecting a high dose of LPS induces lethal 
endotoxic shock in mice. Components of the 
NLRP3 inflammasome (i.e., NLRP3 and ASC) play 
essential roles in this disease model (44-46), 
although IL-1β and IL-18 are dispensable (47,48). 
To test whether PL and PLP can rescue mice from 
lethal endotoxic shock, C57BL/6 mice pretreated 
with PBS (control), PL, or PLP were given an 
injection of 50 mg/kg-bw LPS. Mice pretreated 
with PBS (n=15) died within 2 days after LPS 
injection; notably, the survival was improved in 
mice pretreated with PL or PLP (n=15 each group) 
(Fig. 7G). 
Taken together, these results suggest that PL and 
PLP may inhibit the activity of the NLRP3 
inflammasome in vivo. 
 
DISCUSSION 
In the present study, we showed that the B6 
vitamers PL and PLP inhibit both TLR-induced 
NF-κB activation (signal 1) and NLRP3-mediated 
caspase-1 activation (signal 2), thereby abolishing 
IL-1β production in macrophages. PLP is a 
required cofactor for many metabolic enzymes. 
However, the PLP concentration necessary to 
inhibit IL-1β production was higher than its 
physiological concentrations in humans and mice, 
suggesting that PLP’s inhibition of IL-1β 
production is likely to be pharmacological effect. 
The inhibitory effect of PL and PLP on signal 1 
was not TLR4-specific, since PL and PLP inhibited 
the IL-6 and TNF-α production induced by ligands 
for other TLRs (Fig. 2). While TLR4 activates both 
the MyD88-dependent and TRIF-dependent NF-
κB-activation pathways, TLR2, TLR7, and TLR9 
specifically activate the MyD88-dependent 
pathway, and TLR3 only activates the TRIF-
dependent pathway (49). Thus, it is likely that the 
target of PL and PLP in the NF-κB pathway is a 
common downstream component of the MyD88- 
and TRIF-dependent pathways. In this context, it is 
worth noting that these pathways commonly induce 
the phosphorylation cascade of TAK1-IKK-IκBα, 
thereby degrading IκBα and activating NF-κB (49). 
TAK1 also activates MAP kinases such as JNK and 
p38, which in turn activate the AP-1 transcription 
factor involved in IL-1β gene expression together 
with NF-κB (49). Our results (Fig. 1K) indicate that 
PL and PLP inhibited the LPS-induced TAK1 
phosphorylation, IKK-IκBα pathway, and JNK 
phosphorylation. Taken together, it is likely that PL 
and PLP inhibit signal 1 by targeting TAK1 or a 
molecule upstream of TAK1 but commonly found 
downstream of TLRs. Further study is required to 
determine whether PL and PLP directly target 
TAK1 itself, or a molecule upstream of TAK1. 
Our experiments using bacterial species that 
selectively activate NLRP3, NLRC4, or AIM2 
suggested that PL and PLP specifically inhibited 
the NLRP3 inflammasome. Thus, it is likely that PL 
and PLP target NLRP3 or a more upstream event in 
signal 2. Consistent with this possibility, PL and 
PLP sharply inhibited ASC speck formation, which 
occurs immediately downstream of NLRP3 
activation. K+ efflux and mitochondrial ROS 
generation have been suggested as common 
upstream events of the activation of NLRP3 by 
various activators. Our results indicated that PLP 
inhibited the ATP-induced mitochondrial ROS 
generation, which may contribute to PLP’s 
inhibition of signal 2. However, PL did not affect 
mitochondrial ROS generation. In addition, neither 
PL nor PLP inhibited the ATP- and nigericin-
induced K+ efflux.  
Because it was previously reported that NLRP3 
is recruited to mitochondria upon activation (50), 
we investigated whether PL and PLP affect the 
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mitochondrial localization of NLRP3 in peritoneal 
macrophages treated with LPS and/or ATP. In our 
hands, a portion of NLRP3 localized at 
mitochondria after induction of NLRP3 expression 
by LPS, and ATP stimulation did not change the 
amount of mitochondrial NLRP3. Furthermore, 
neither PL nor PLP affected the amount of 
mitochondrial NLRP3, when PL or PLP was added 
after LPS stimulation but before ATP stimulation 
(data not shown). 
We also sought to determine whether PL and 
PLP affected the interaction of NLRP3 and ASC or 
post-translational modification of NLRP3 such as 
ubiquitination or tyrosine phosphorylation (51). 
However, in our hands, these responses of 
endogenous NLRP3 in peritoneal macrophages 
were hardly or barely detectable levels (data not 
shown) so that we could not obtain conclusive 
answers to these questions at this moment. Thus, 
further study is required to determine the direct 
target of PL in inhibiting signal 2. 
Importantly, vitamin B6 suppressed the IL-1β 
production in vivo and protected mice from LPS-
induced endotoxic shock. In our experiments on 
LPS-induced IL-1β production, PL and PLP were 
administered with the LPS injection. However, PL 
and PLP did not significantly suppress the TNF-α 
production, which requires only signal 1, 
suggesting that PL and PLP suppressed the in vivo 
IL-1β production primarily by inhibiting signal 2. 
In addition, it has been demonstrated that 
components of the NLRP3 inflammasome play 
important roles in LPS toxicity (44-46), while IL-
1β and IL-18 are dispensable for it (47,48). 
HMGB1, an alarmin released from dead cells, was 
recently revealed to play an important role in LPS 
toxicity (52). Because HMGB1 is released by 
pyroptosis, the delay of pyroptosis by PL and PLP 
might also have played a role in protecting mice 
from LPS toxicity. Finally, because NLRP3 has 
been suggested to play pathological roles in various 
inflammation-related diseases, PL and PLP might 
have clinical value in treating these diseases.  
 
EXPERIMENTAL PROCEDURES 
Mice—ICR mice and C57BL/6J mice were 
purchased from Japan SLC (Shizuoka, Japan). All 
protocols for animal studies were approved by the 
Kanazawa University Committee on Animal 
Welfare. 
Reagents—PL hydrochloride, PN hydrochloride, 
PLP (Nacalai Tesque, Kyoto, Japan), PM 
dihydrochloride (Calbiochem La Jolla, CA, USA), 
LPS from E. coli K235 and from E. coli 0111:B4, 
ATP, nigericin, poly(I:C) (Sigma-Aldrich, St. 
Louis, MO), Pam3CSK4, R837 (InvivoGen, San 
Diego, CA), CpG oligodeoxynucleotides (Genset 
Oligos, La Jolla, CA), and MSU (Wako, Osaka 
Japan) were purchased. 
Macrophage preparation and stimulation—
C57BL/6J mice aged 8-12 weeks were injected i.p. 
with 3% thioglycollate solution, and peritoneal 
exudate cells were collected 4 d later. The cells 
(5×104 cells/well) were cultured in a 96-well plate 
for 3 h, after which non-adherent cells were 
removed by aspiration to enrich for macrophages. 
Human THP-1 cells were treated with 100 nM 
PMA for 3 h. The PMA-treated THP-1 cells were 
seeded in a 96-well plate (5×104 cells/well) and 
cultured overnight without PMA to allow them to 
differentiate into macrophagic cells. Cells were 
cultured in RPMI 1640 medium supplemented with 
10% FCS, 100 U/ml penicillin, and 100 µg/ml 
streptomycin (Meiji Seika, Tokyo, Japan). 
To test vitamin B6’s inhibition of signal 1, 
mouse macrophages were cultured with a B6 
vitamer (500 µM unless otherwise specified) for 24 
h and then with LPS (from E. coli K235, 0.5 µg/ml 
for all in vitro stimulations) for 16 h. To test the 
inhibitory activity of vitamin B6 on other TLR 
ligands, mouse macrophages were cultured with a 
B6 vitamer for 2 h and then with various TLR 
agonists for 6 h. THP-1 macrophages were treated 
sequentially with a B6 vitamer for 2 h, LPS for 4 h, 
and nigericin (5 µM) for 30 min.  
To test the inhibitory activity of vitamin B6 on 
signal 2, mouse macrophages were treated with 
LPS for 16 h, with a B6 vitamer for 2 h, and with 
various inflammasome activators for 6 h. THP-1 
macrophages were treated with LPS for 4 h, with a 
B6 vitamer for 2 h, and with nigericin for 30 min. 
To induce noncanonical NLRP3-inflammasome 
formation, peritoneal macrophages were primed 
with 1 μg/ml Pam3CSK4 for 5 h, washed once with 
fresh medium, and then treated with or without 500 
μM PL or PLP for 1h. Finally, cells were 
transfected with LPS (2 μg/ml) using FuGene HD 
(Promega, Madison WI) and cultured for 18 h. 
Bacterial Infection—S. aureus (Smith strain, 
kindly provided by Dr. Nakanishi, Kanazawa 
University, Kanazawa, Ishikawa, Japan) and S. 
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typhimurium (ATCC 14028) in the log phase were 
used for infection. L. monocytogenes (EGD, 
serovar 1/2a) was cultured in brain-heart infusion 
broth (Eiken Chemical, Tokyo, Japan), collected in 
the log phase, washed with PBS, suspended in PBS 
supplemented with 10% glycerol, and stored in 
aliquots at -80°C. Bacterial stocks were thawed and 
diluted in RPMI 1640 medium just prior to 
infecting macrophages (35). 
The peritoneal macrophages were placed in 
antibiotic-free medium in 96-well plates and 
infected with the bacteria. The plates were briefly 
centrifuged to improve interactions between the 
cells and bacteria. Penicillin G (100 U/ml), 
streptomycin (100 µg/ml), and gentamycin (50 
µg/ml, Thermo Fisher Scientific, Waltham, MA) 
were added 1 h after infection with S. aureus or S. 
typhimurium, and the cells were further cultured for 
5 h. To activate AIM2, peritoneal macrophages 
were infected with L. monocytogenes. Finally, 
penicillin G (100U/ml) was added to the culture to 
facilitate intracellular bacterial DNA release, and 
the cells were further cultured for 3 h. 
Real—time PCR—Total RNA was purified from 
mouse macrophages using TRIZOL reagent 
(Thermo Fisher Scientific), and cDNA was 
synthesized using the First Strand cDNA Synthesis 
kit (Toyobo, Osaka, Japan). Real-time PCR was 
performed using the StepOne Real-Time PCR 
System (Thermo Fisher Scientific) with the 
THUNDERBIRD SYBR qPCR Mix (Toyobo) and 










TCTTCCTGGAGCGCTTCTAA-3’; and Gapdh, 
5’-CAATGACCCCTTCATTGACC-3’ and 5'-
TGGAAGATGGTGATGGGATT-3’. 
ELISA and LDH analysis—The concentrations 
of mouse and human IL-1β, IL-6, and TNF-α in 
culture supernatants were determined using 
OptEIA ELISA kits (BD Pharmingen, San Diego, 
CA) according to the manufacturer’s protocols. The 
mouse IL-18 ELISA kit was purchased from MBL 
(Nagoya, Japan). Cell death was determined by 
measuring LDH activity in the culture medium 
using the CytoTox96 NonRadioactive Cytotoxicity 
Assay (Promega). 
Western blot analysis—Cells were lysed in Tris-
buffered saline containing 1% NP-40 and complete 
protease inhibitor cocktail (Roche Diagnostics 
GmbH, Mannheim, Germany) for 30 min on ice. 
Lysates were centrifuged at 12,000 × g for 10 min 
to remove debris and then boiled in Laemmli 
sample buffer for 5 min. Proteins were separated by 
SDS–PAGE and transferred to PVDF membranes. 
Membranes were incubated for 1 h in a blocking 
buffer (5% skim milk, 0.05% Tween 20 in Tris-
buffered saline) or in Blocking One-P (for 
phosphoprotein detection, Nacalai Tesque), 
followed by the addition of a primary antibody 
against IL-1β (Santa Cruz Biotechnology, Dallas, 
TX), caspase-1 (Santa Cruz Biotechnology, Santa 
Cruz, CA), NLRP3 (Enzo Life Science, 
Villeurbanne, France), IκBα, phospho-TAK1, JNK, 
phospho-JNK, IKKα, IKKβ, phospho-IKKα/β 
(Cell Signaling, Danvers, MA), or GAPDH (Novus 
Biologicals, Littleton, CO). Antibodies were 
detected by a horseradish-peroxidase-conjugated 
goat anti-mouse or anti-rabbit secondary antibody 
(Jackson Immunoresearch Laboratories, West 
Grove, PA) using enhanced chemiluminescence 
(Thermo Fisher Scientific). 
To detect ASC oligomerization, cells were lysed 
with Tris-buffered saline (TBS) containing 0.5% 
Triton X-100, and centrifuged at 6,000 × g at 4 °C 
for 15 min. Supernatants (lysates) were transferred 
to new tubes. The pellets were washed with TBS 
twice and then crosslinked at 37 °C for 45 min by 
disuccinimidyl suberate (DSS, 2mM, Thermo 
Fisher Scientific). The crosslinked pellets were 
spun down at 6,000 × g for 15 min, dissolved in 
SDS-containing sample buffer, and subjected to 
SDS-PAGE and Western blot using anti-ASC 
antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA). 
Immunofluorescence confocal microscopy—
Mouse ASC was detected using a rat mAb (46) 
followed by FITC-conjugated goat anti-rat IgG 
(American Qualex, San Clemente, CA). Nuclei 
were stained by DAPI (Dojindo, Kumamoto, 
Japan). The stained cells were examined under a 
laser scanning microscope (LSM 510 META with 
EC Plan-Neofluar 40x/0.75; Carl Zeiss, Jena, 
Germany) equipped with 488 nm argon, 543 nm 
HeNe, 633 nm HeNe, and Blue Diode 405 lasers. 
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Images were acquired and analyzed using Zen2009 
software. 
Determination of intracellular potassium 
levels—Cells (6 x 105 cells/well in a 24-well plate) 
were lysed in 3% ultrapure HNO3 (600 µl) for 30 
min on ice. Lysates were diluted 10 times with 
ultrapure H2O, and potassium concentrations were 
determined by inductively coupled plasma mass 
spectrometry (SPQ-9000, Seiko Instruments, Chiba, 
Japan) using KCl solution as a standard. 
Determination of mitochondrial ROS levels—
Mitochondrial ROS levels were measured using 
MitoSox Red (Thermo Fisher Scientific) according 
to the manufacturer’s protocol. Data were acquired 
with a FACSCanto II (BD Biosciences, San Jose, 
CA) and analyzed with FlowJo software (FlowJo, 
Ashland, OR). 
In vivo experiments—The Food and Nutrition 
Board of the Institute of Medicine proposed a 
tolerable upper limit of 100 mg/day of vitamin B6 
for adult humans (53). Based on this and the 
conversion between human doses and animal-
equivalent doses according to body surface area 
(54), we estimated a tolerable vitamin B6 dose of 
20 mg/kg-body weight (bw)/day for mice; this was 
the dose used for the in vivo experiments in the 
present study. ICR mice were i.p. injected first with 
PL or PLP, 2 h later with LPS (from E. coli 0111:B4, 
2 µg/kg-bw), and 90 min afterward with 10 ml/kg-
bw of 5 mM ATP (50 µmole/kg-bw). Serum and 
peritoneal lavage samples were collected 1 h after 
the ATP injection. C57BL/6 mice were i.p. injected 
with LPS (20 mg/kg-bw) with or without PL or PLP, 
and serum and peritoneal lavage samples were 
collected 3 h later. Lethal endotoxic shock was 
induced in C57BL/6 mice by i.p. LPS injection (50 
mg/kg-bw, from E. coli 0111:B4, Sigma-Aldrich). 
Statistical analysis—Data were analyzed using 
GraphPad Prism 6.05 (GraphPad Software, La Jolla, 
CA). Difference between a control and an 
experimental group was examined by one-way 
ANOVA and Dunnett’s test. Difference between 
mouse survival curves was evaluated by the log-
rank (Mantel-Cox) test. P < 0.05 was considered 
significant. 
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FIGURE 1. PL and PLP suppress signal 1. A and B, Peritoneal macrophages were treated with the 
indicated B6 vitamers (500 µM in A, and the indicated concentrations in B) for 24 h, then stimulated with 
LPS for 16 h, and finally exposed to 5 mM ATP for 6 h. The IL-1β concentration in culture supernatants 
was determined by ELISA. C-E, Peritoneal macrophages were treated with B6 vitamers for 24 h and then 
stimulated with LPS for 16 h. ProIL-1β and GAPDH (loading control) were detected by Western blot (C). 
The IL-6 and TNF-α concentrations in culture supernatants were determined by ELISA (D and E). F-J, 
Peritoneal macrophages were treated with B6 vitamers for 24 h and then stimulated with LPS for 16 h, after 
which the Il1b, Il6, Ptgs2, Ccl2 and Nlrp3 mRNAs were quantified by real-time PCR. K, Peritoneal 
macrophages were treated with PL or PLP for 2 h and then stimulated with LPS for the indicated times. 
The total and/or phosphorylated forms of TAK1, IKKs, IkBα, and JNKs were detected by Western blot. A, 
B and D-J, Data show mean + SD; n=3. Asterisks indicate significant differences (**p < 0.01) from the 
control group (c). All experiments were repeated at least three times, and representative data are shown. 
 
FIGURE 2. PL and PLP suppress the IL-6 and TNF-α production induced by TLR ligands. A-H, 
Peritoneal macrophages were incubated with PL or PLP for 2 h and then stimulated with poly I:C (20 µg/ml), 
Pam3CSK4 (10 µg/ml), R837 (10 µg/ml), or CpG oligodeoxynucleotides for 6 h (1 µM). IL-6 and TNF 
were measured by ELISA. Data show mean + SD; n=3. Asterisks indicate significant differences (**p < 
0.01) from the control group (c). All experiments were repeated at least three times, and representative data 
are shown. 
 
FIGURE 3. PL and PLP suppress signal 2. A-E, Peritoneal macrophages were sequentially incubated with 
LPS for 16 h, B6 vitamers for 2 h, and ATP (5 mM), nigericin (5 µM), R837 (10 µg/ml), or MSU (150 
µg/ml) for 6 h. IL-1β, IL-18, and IL-6 in culture supernatants were quantified by ELISA. F, Mouse 
peritoneal macrophages were exposed to LPS for 16 h, then incubated with PL or PLP for 2 h, and finally 
stimulated with ATP for 10, 20, or 30 min). Whole cell lysates were collected and subjected to Western 
blot using antibodies against phosphorylated forms of IKKα/β, TAK1, and IκBα, and total IκBα. GAPDH 
serves as a loading control. G, Peritoneal macrophages were treated with LPS for 16 h, then incubated with 
PL or PLP for 2 h, and finally exposed to ATP (5 mM) for 30 min. Pro-IL-1β, mature IL-1β, caspase-1, and 
GAPDH in cell lysates were detected by Western blot. H and I, Peritoneal macrophages were sequentially 
incubated with LPS for 16 h, B6 vitamers for 2 h, and ATP (5 mM) for 1 h, 2 h, 3 h, or 6 h. IL-1β in culture 
supernatants were quantified by ELISA (H). Cell death was evaluated by assaying LDH release (I). A-E, H 
and I, Data show mean + SD; n=3. Asterisks indicate significant differences (**p < 0.01) from the control 
group (c). All experiments were repeated at least three times, and representative data are shown. 
 
FIGURE 4. PL and PLP selectively suppress the NLRP3 inflammasome. A and B, Peritoneal 
macrophages were incubated with PL or PLP for 24 h and then infected with S. aureus (S.a.) with a 
multiplicity of infection (MOI) of 100 or S. typhimurium (S.t.) with a MOI of 20. C and D, Peritoneal 
macrophages were primed with LPS for 16 h, then incubated with PL or PLP for 2 h, and finally infected 
with S. aureus (MOI 50) or S. typhimurium (MOI 20). E, Peritoneal macrophages were infected with L. 
monocytogenes (L.m., MOI 2) for 4 h and then incubated with PL or PLP for 2 h, after which penicillin G 
(100U/ml) was added to facilitate intracellular bacterial DNA release. F and G, wild-type (WT) and ASC-
/- peritoneal macrophages were primed with Pam3CSK4 (1µg/ml) for 5h, then incubated with PL or PLP 
for 1 h, and finally transfected with LPS (2 µg/ml) using FuGene HD for 18 h. IL-1β in culture supernatants 
was quantified by ELISA (A-F). Cell death was evaluated by assaying LDH release (G). Data show mean 
+ SD; n=3. Asterisks indicate significant differences (**p < 0.01) from the control group (c). All 
experiments were repeated at least three times, and representative data are shown. 
 
FIGURE 5. PL and PLP suppress signal 1 and signal 2 in human cells. A and B, THP-1 macrophages 
were treated with PL or PLP for 2 h, then incubated with LPS for 4 h, and finally stimulated with nigericin 
(5 µM) for 0.5 h. C and D, THP-1 macrophages were primed with LPS for 4 h, then treated with PL or PLP 
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for 2 h, and finally stimulated with nigericin (5 µM) for 0.5 h. A-D, IL-1β and TNF-α in culture supernatants 
were measured by ELISA. Data show mean + SD; n=3. Asterisks indicate significant differences (**p < 
0.01) from the control group (c). All experiments were repeated at least three times, and representative data 
are shown. 
 
FIGURE 6. Effects of PL and PLP in ASC speck formation, ASC oligomerization, K+ efflux, and 
mitochondrial ROS generation. A and B, Peritoneal macrophages cultured on glass coverslips in 24-well 
plates were primed with LPS for 16 h, then treated with PL or PLP for 2 h, and finally exposed to nigericin 
(5 µM) for 1 h. ASC specks (FITC) and nuclei (DAPI) were visualized using a confocal fluorescence 
microscope (A). Total cells and cells with ASC aggregates (specks) were counted in 4 microscope fields 
per group, and data show mean + SD (B). C, Peritoneal macrophages were primed with LPS for 16 h, then 
treated with PL or PLP for 2 h, and finally exposed to nigericin (5 µM) for 1 h. Cells were lysed with 0.5% 
Triton X-100 in TBS, and centrifuged. The supernatants (lysates) and DSS-crosslinked pellets were 
subjected to Western blot using antibodies against ASC and GAPDH. D, Peritoneal macrophages were 
primed with LPS for 16 h, then treated with PL or PLP for 2 h, and finally exposed to ATP (5 mM) or 
nigericin (5 µM) for 0.5 h. Intracellular K+ levels relative to those in cells treated with LPS only were 
determined using inductively coupled plasma mass spectrometry.  E and G, Peritoneal macrophages primed 
with LPS for 16 h were detached from the culture plate, and the single-cell suspension was treated with 
Mito-TEMPO (500 µM, E) or PL or PLP (G) for 2 h, after which the cells were exposed to ATP (5 mM) in 
the presence of MitoSOX (5 µM) for 10 min. Fluorescence intensities were analyzed by flow cytometry. F, 
Peritoneal macrophages were primed with LPS for 16 h, then incubated with Mito-TEMPO (500 µM) for 
2 h, and finally exposed to ATP (5 mM), 5 µM Nigericin, 150 µg/ml MSU, or 10 µg/ml R837 for 6 h. 
Supernatant IL-1β content was measured by ELISA. B, D and F, Data show mean + SD; n=3. Asterisks 
indicate significant differences (**p < 0.01) from the control group (c). All experiments were repeated at 
least three times, and representative data are shown. 
 
FIGURE 7. PL and PLP suppress IL-1β production in vivo. A and B, ICR mice aged 8 weeks were i.p. 
injected first with PBS (solvent control), PL, or PLP; then 2 h later with  PBS or LPS (2 µg/kg-bw); and 90 
min after that with PBS or ATP (50 µmole/kg-bw). After 1 h, serum and peritoneal lavage samples were 
collected, and the IL-1β was quantified by ELISA (n=11 mice for the PBS group; n=16-18 mice for the 
other groups). C-F, C57BL/6 mice aged 10 weeks were i.p. injected with PBS or LPS (20 mg/kg-bw) alone 
or with PL or PLP; serum and peritoneal lavage samples were collected 3 h later and analyzed by ELISA 
for IL-1β (C and D) or TNF-α (E and F); n=4 mice for the PBS group; n=9 mice for the other groups. G, 
C57BL/6 mice aged 8 weeks were i.p. injected with PBS, PL, or PLP, and challenged with LPS (50 mg/kg-
bw) 2 h later (n=15 mice for each group). A-G, *p < 0.05; **p < 0.01. All experiments were repeated at 
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